Bio Vitos Pharma AB (publ) (STO:BIOVIT)

Bio Vitos Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.41	3	4.74	3.52	2.9
Revenue Growth (YoY)	-86.29%	-36.82%	34.72%	21.41%	-41.73%
Cost of Revenue	0.05	1.01	1.1	0.5	0.26
Gross Profit	0.36	1.98	3.64	3.02	2.64
Selling, General & Admin	3.48	5.49	11.42	10.55	8.66
Operating Expenses	18.34	14.91	18.57	17	14.34
Operating Income	-17.98	-12.92	-14.93	-13.99	-11.7
Interest Expense	-	-0	-0	-0	-0.03
Interest & Investment Income	0.03	0.06	0.03	0.03	0.03
Earnings From Equity Investments	-1.92	-	-	-	-
Other Non Operating Income (Expenses)	-	0	-0	-0	-
Pretax Income	-19.86	-12.87	-14.9	-13.95	-11.7
Net Income	-19.86	-12.87	-14.9	-13.95	-11.7
Net Income to Common	-19.86	-12.87	-14.9	-13.95	-11.7
Shares Outstanding (Basic)	40	6	3	2	2
Shares Outstanding (Diluted)	40	6	3	2	2
Shares Change (YoY)	609.36%	114.80%	36.45%	21.65%	-
EPS (Basic)	-0.50	-2.30	-5.71	-7.30	-7.45
EPS (Diluted)	-0.50	-2.30	-5.71	-7.30	-7.45
Free Cash Flow	-2.9	-3.97	-7.91	-8.19	-8.52
Free Cash Flow Per Share	-0.07	-0.71	-3.03	-4.28	-5.42
Gross Margin	88.31%	66.21%	76.83%	85.76%	91.03%
Operating Margin	-4377.66%	-431.43%	-314.91%	-397.45%	-403.63%
Profit Margin	-4837.44%	-429.54%	-314.27%	-396.52%	-403.58%
Free Cash Flow Margin	-705.40%	-132.49%	-166.76%	-232.65%	-293.96%
EBITDA	-3.11	-12.31	-14.32	-13.44	-11.32
D&A For EBITDA	14.86	0.62	0.61	0.54	0.38
EBIT	-17.98	-12.92	-14.93	-13.99	-11.7
Revenue as Reported	-	3	4.74	3.52	2.9

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.